Sodium Chloride Injection 23.4%Pronunciation
Dosage Form: injection, solution, concentrate
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
CONCENTRATED SODIUM CHLORIDE INJECTION, USP
23.4% (4 mEq per mL)
|100 mL PHARMACY BULK PACKAGENOT FOR DIRECT INFUSION|
Sodium Chloride Injection 23.4% Description
Concentrated Sodium Chloride Injection, USP 23.4% is sterile, preservative free, nonpyrogenic, solution of Sodium Chloride in water for injection. Each mL contains: Sodium Chloride 234 mg (4 milliequivalents), Water for Injection, q.s. pH adjusted with Hydrochloric Acid and/or Sodium Hydroxide. It is intended for dilution use only.
(1 mL diluted with 25 mL of Water for Injection will give approximately 308 mOsmol/mL).
Unused amount of the 30 mL Single Dose Vial should be discarded immediately following withdrawal of any portion of contents.
The 100 mL Pharmacy Bulk Package contains many single doses for use in a pharmacy admixture program in the preparation of parenteral fluids.
Sodium Chloride Injection 23.4% - Clinical Pharmacology
Sodium Chloride in water dissociates to provide sodium (Na+) and chloride (Cl¯) ions. Sodium (Na+) is the principle cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl¯) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na+) and chloride (Cl¯) are largely under the control of the kidney which maintains a balance between intake and output.
Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirements range from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).
Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.
Indications and Usage for Sodium Chloride Injection 23.4%
Concentrated Sodium Chloride Injection, USP 23.4% is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirement of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, determine the appropriate number of milliequivalents of Concentrated Sodium Chloride Injection, USP and dilute for use.
Concentrated Sodium Chloride Injection, USP is hypertonic, and must be diluted before use. Inadvertent direct injection or absorption of Concentrated Sodium Chloride Injection, USP may give rise to sudden hypernatremia and such complications as cardiovascular shock, central nervous system disorders, extensive hemolysis, cortical necrosis of the kidneys and severe local tissue necrosis (if administered extravascularly). Do not use unless solution is clear. No preservative added.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.
Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
Category C. Animal reproduction studies have not been conducted with Sodium Chloride. It is also not known whether Sodium Chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride should be given to a pregnant woman only if clearly needed.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Sodium Chloride Injection 23.4% Dosage and Administration
Concentrated Sodium Chloride Injection, USP is Strongly Hypertonic And Must Be Diluted Prior To Administration (See WARNINGS). The dosage of Concentrated Sodium Chloride Injection, USP as an additive in parenteral fluid therapy is predicated on the specific requirement of the patient after necessary clinical and laboratory information is considered and correlated. The appropriate volume is then withdrawn for proper dilution. Having determined the milliequivalents of Sodium Chloride to be added, divide by four to calculate the number of milliliters (mL) of concentrated solution to be used. Withdraw this volume aseptically and transfer this additive solution into appropriate intravenous solutions such as 5% dextrose injection. The properly diluted solutions may be given intravenously or subcutaneously.
DIRECTIONS FOR DISPENSING FROM 100 mL PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION
The 100 mL Pharmacy Bulk Package is for use in a Pharmacy Admixture Service only. The 100 mL Pharmacy Bulk Package should be suspended (inverted) by its IV hang label in a laminar flow hood or biological safety cabinet. Prior to entering a Pharmacy Bulk Package remove the flip-off seal and cleanse the rubber closure with a suitable antiseptic agent. Entry into the Pharmacy Bulk Package must be made with a sterile transfer set or other sterile dispensing device and the contents dispensed in aliquots using aseptic technique. Use of a syringe needle is not recommended as it may cause leakage. ANY UNUSED PORTION MUST BE DISCARDED WITHIN 4 HOURS AFTER INITIAL ENTRY. The date and the time initially opened should be recorded in the space provided on the Pharmacy Bulk Package label.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Use only if solution is clear and seal intact.
Concentrated Sodium Chloride Injection, USP 23.4% (4 mEq per mL). No preservative added.
NDC 0517-2930-25 30 mL Single Dose Vials Packed in boxes of 25
NDC 0517-2900-25 100 mL Pharmacy Bulk Package Packed in boxes of 25
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).
SHIRLEY, NY 11967
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
PRINCIPLE DISPLAY PANEL – 30 mL Container
23.4% (234 mg/mL)
30 mL SINGLE DOSE VIAL
FOR IV OR SC USE
AMERICAN REGENT, INC.
SHIRLEY, NY 11967
sodium chloride injection, solution, concentrate
|Labeler - American Regent, Inc. (622781813)|
|Luitpold Pharmaceuticals, Inc.||002033710||ANALYSIS(0517-2930), MANUFACTURE(0517-2930), STERILIZE(0517-2930)|
More about sodium chloride
- Sodium Chloride (AHFS Monograph)
- Sodium Chloride 0.45% Injection (FDA)
- Sodium Chloride Inhalation Solution (FDA)
- Sodium Chloride Injection 0.45% (FDA)
- Sodium Chloride Injection Hospira (FDA)
- Sodium Chloride Intravenous Infusion (FDA)